頁籤選單縮合
題名 | Effect of Mirabegron on Erectile Function in Sexually Active Men with Bothersome Overactive Bladder Symptoms= |
---|---|
作者 | Wu, Tsung-hsien; Shen, Yuan-chi; Lee, Wei-chia; Wang, Hung-jen; Chuang, Yao-chi; Wang, Hung-jen; Shen, Yuan-chi; Wu, Tsung-hsien; Chuang, Yao-chi; Lee, Wei-chia; |
期刊 | Journal of the Chinese Medical Association |
出版日期 | 20200100 |
卷期 | 83:1 2020.01[民109.01] |
頁次 | 頁55-59 |
分類號 | 418.22 |
語文 | eng |
關鍵詞 | Erectile function; Mirabegron; Overactive bladder; |
英文摘要 | Background: To evaluate the change of erectile function (EF) in sexually active male overactive bladder (OAB) patients treated with Mirabegron. Mirabegron, a selective β3 adrenoceptor agonist, approved for the treatment of OAB, has been reported to relax human and rat corpus cavernosum and might have beneficial effect on EF. Methods: A total of 128 consecutive men with lower urinary tract symptoms attended urology outpatient clinic were evaluated for OAB and EF. Thirty-four sexually active OAB patients were prospectively enrolled in this study and received mirabegron 50mg oral once a day. The evaluation of EF and OAB was based on a self-administered questionnaire containing International Index of Erectile Function (IIEF-5) and OAB symptom score (OABSS), respectively. Men with an OABSS urgency score of ≥2 and sum score of ≥3 were considered to have OAB. The therapeutic outcomes were assessed at baseline, 4, and 12 weeks. Results: Mirabegron usage was associated with a statistically significant improvement of OAB symptoms (OABSS 32.1% decrease) at 4-week follow-up and the therapeutic effects were maintained at 12-week follow-up. Mirabegron usage did not improve EF (IIEF-5 4.9% decrease at 4-week; p = 0.106, and 9.1% decrease at 12-week follow-up; p = 0.077). However, the IIEF-5 was significantly decreased in the higher baseline IIEF-5 (≥17) group (11.7% decrease; p = 0.044), noncoronary artery disease (13.2%; p = 0.007), or non-DM group (13.9% decrease; p = 0.021) at 12-week follow-up. Conclusion: This preliminary study demonstrates that mirabegron treatment of men with OAB improved OAB symptoms, but has no beneficial effect on EF. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。